Biochemical and Molecular Studies on Prehypertension and its Risk for Cardiometabolic Syndrome

Abstract

Prehypertension is an emerging public health concern with a strong relation towards hypertension and Cardiovascular eventsand it is one of the important potential candidates and independent predictor for both cardiovascular and cerebrovascular diseases. Hence management of prehypertension through the prevention and early detection is very important for the public health. The present study was aimed to identify the various biochemical and molecular biomarkers for the early detection of Cardio Metabolic Syndrome (CMS) among subjects with prehypertension and to assess the predictive role of Adiponectin and Interleukin-6 (IL-6) among,prehypertensive subjects for the risk of Cardiometabolic Syndrome. newlineThe study group included 157 clinically diagnosed prehypertensive subjects and 100 age and sex matched healthy control subjects. Biochemical, physiological investigations as well as inflammatory and oxidative risk markers along with emerging biomarker like adiponectin and interleukin-6 showed a statistically significant difference between study subjects and control subjects. newlineConventional risk factors, family history and sedentary lifestyle etc.had direct association with CMS. The increased mean CBMN frequency among the study subjects with 95% of confidence interval revealed its predictability for CMS. newlineIn short, the current study demonstrated that, prehypertension and oxidative stress together play an important role which leads to cardiometabolic syndrome. Thus it can be concluded that dietary modification, changes in life style characters and proper medication can reduce the risk of CMS occurring among prehypertensive subjects. An earlier diagnosis and treatment is necessary to prevent CMS events by evaluating emerging risk markers such as adiponectin and interleukin-6. Early targeting of prehypertensive individuals and the adherence to lifestyle modifications may provide significant long-term benefits in the management of prehypertension. newline